An FDA Advisory Committee recommended the approval of Canagliflozin, CAS# 842133-18-0, for the treatment of type 2 diabetes. The approval in January 2013 was an encouraging move for Johnson and Johnson, who will market Canagliflozin as the brand Invokana. As an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least[…]
New Canagliflozin Once Daily Tablet Treatment for Type 2 Diabetes
Anti-Diabetic, Drug Research & Development API Tags: canagliflozinsitagliptintype 2 Diabetes Mar 28, 2013
Lixisenatide Approved By the EU and Being Reviewed By the FDA
Anti-Diabetic, Drug Research & Development API, EU Approved 2013, NDA Tags: HbA1cNew Drug Applicationtype 2 Diabetes Feb 27, 2013
As a treatment for Type 2 diabetes lixisenatide is approved by the EU and currently under review as a New Drug Application {NDA} by the FDA. Sanofi is preparing to launch lixisenatide in the European Union as in the latter of first quarter 2013, with the proprietary name Lyxumia. What makes lixisenatide unique is not[…]
Alogliptin Shines in Three Recent FDA Approvals
Anti-Diabetic, Blood Product, Drug Research & Development API, Gliptin Tags: JanuviaMetformin Hydrochloridetype 2 Diabetes Feb 06, 2013
Alogliptin is a current newsmaker in the pharmaceutical industry. On January 25, 2013 Takeda announced that Alogliptin, CAS# 850649-62-6, was approved alongside Metformin HCl, CAS# 1115-70-4, in the novel type 2 diabetes medication Kazano. As an efficacious and highly selective DPP-4 inhibitor, Alogliptin, when combined in this single dose tablet with metformin HCI effectively aids[…]
Saxagliptin Has a Promising Future
Anti-Diabetic, Drug Research & Development API, FDA Approved 2009 Tags: Saxagliptintype 2 Diabetes Jan 04, 2013
Saxagliptin, also known as the brand name Onglyza, is an oral diabetes medication for people with type 2 diabetes. Saxagliptin can help to control blood sugar levels, but is not a treatment for type 1 diabetes. Side effects of saxagliptin are mild, and may include a headache, stuffy or runny nose and a sore throat.[…]
Trelagliptin Succinate – a Potential Once a Week Type 2 Diabetes Drug
Blood Glucose Regulator, Blood Product, Gliptin Tags: Januviasitagliptintype 2 Diabetes Nov 05, 2012
Cases of Diabetes, particularly type 2 Diabetes have skyrocketed worldwide and in the United States. According to the National Diabetes Information Clearinghouse Diabetes affects 25.8 million people of all ages, or roughly 8.3 percent of the U.S. population. The majority of these cases in the United States, upwards of 90 percent, are of the type[…]
Linagliptin and Metformin Hydrochloride Tag Team to Combat Type 2 Diabetes
Anti-Diabetic, Antibiotic, Blood Glucose Regulator, Drug Research & Development API, Gliptin Tags: LinagliptinMetformin Hydrochloridetype 2 Diabetes Aug 17, 2012
As a chronic disease which occurs when the body does not properly produce, or use the hormone insulin, type 2 diabetes has become a worldwide problem. Roughly 25.8 million Americans and an estimated 366 million people worldwide have diabetes, according to the CDC and 2011 data from the IDF. Type 2 diabetes accounts for 90-95[…]
Glipizide Needed to Meet Growing Numbers of Patients with Type 2 Diabetes
Anti-Diabetic, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2014 Tags: type 2 Diabetes May 21, 2012
Glipizide, CAS number 29094-61-9, is also known as Glucotrol XL, which is marketed by Pfizer. With the patent due to expire in January of 2014, glipizide is set up for success as a generic alternative treatment for patients with type 2 diabetes. As an oral blood-glucose-lowering drug of the sulfonylurea class, glipizide is offered in[…]
Dapagliflozin FDA Review For Type 2 Diabetes Treatment
Anti-Diabetic, Drug Research & Development API, NDA Tags: Dapagliflozintype 2 Diabetes Feb 29, 2012
Dapagliflozin, CAS number 461432-26-8, is currently being reviewed by the FDA for treatment of type 2 diabetes in adults. Developed by Bristol-Myers Squibb and AstraZeneca, the method of action of dapagliflozin is to inhibit the subtype 2 of the sodium-glucose transport proteins, or SGLT2. This particular subtype is responsible for at least 90% of the[…]
Liraglutide diabetes control is proven and leads to weight loss
Anti-Diabetic, Drug Research & Development API Tags: anti-diabeticDrug AdministrationLiraglutidetype 2 Diabetes Dec 28, 2010
Liraglutide Diabetes Control Liraglutide is a newly developed drug that is used to control the levels of blood glucose in patients suffering from type 2 Diabetes. In January 2010, the US Food and Drug Administration approved this drug for the treatment of patients with diabetes. Liraglutide was approved by the European Medicines Agency (EMEA) in[…]
Metformin Hydrochloride Studies
Anti-Diabetic, Blood Glucose Regulator, OTC and Compounding Product, TEVA API Tags: anti-diabeticLDLMetformin HydrochlorideObesitytype 2 Diabetes Dec 08, 2010
Metformin Hydrochloride is one of the most recommended medicines for the treatment of patients suffering from biguanide or type 2 Diabetes. According to recent studies, Metformin Hydrochloride reduces the LDL and triglyceride levels in the blood and hence it is one of the best medicines for diabetic patients who are also suffering with obesity. Studies[…]
